Ovarian cancer is the eighth most common malignancy in women worldwide with a mortality rate of over 140,000 deaths per year.
Ovarian cancer is the eighth most common malignancy in women worldwide with a mortality rate of over 140,000 deaths per year. 1 Borderline ovarian tumors (BOT) are recognized as a vague entity of ovarian tumors between benign and malignant tumors. BOTs are typically detected 20 years earlier than invasive ovarian carcinoma. 2 The annual incidence of BOT is 1.5-2.5 per 100,000 and approximately 3,000 cases of BOT are diagnosed each year in the United States. 3 Since the 1970s BOT has become more common among white women of reproductive age.
BOT is classified into five categories among which the most common types are serous and mucinous. For the serous type, 70% of cases are stage I with a survival rate of almost 100% and 30% are advanced stage with a survival rate of 95.3%. For the mucinous type, 82% of cases are stage I with a survival rate of 99-100% and 18% are advanced stages with a survival rate of 50%. 4 Some studies have reported that the recurrence rate for BOT ranges from 8% to 32%. 5 Hereditary ovarian cancer represents approximately 10% of all epithelial ovarian cancers. 6, 7 The two most common 
Materials and Methods
Thirty-four women with BOT and available tumor blocks Finally, 32 cases were analyzed for the following demographic characteristics: age, menopause, parity, CA-125 level, and progression-free survival (PFS). We used chi-square or Fisher exact test for categorical variables.
A P value < 0.05 was considered statistically significant.
Statistical analyses were performed with SPSS software (version 12.0; SPSS Inc., Chicago, IL, USA).
Results
Among the 34 cases with available tumors, two cases were excluded due to incomplete data. The demographic characteristics for the 32 patients are listed in Regarding histology, 14 patients (44%) were serous type, and 18 (56%) were mucinous type (Table 2) .
Patients were classified into three groups by operation method: unilateral ovarian cystectomy (UOC), unilateral salpingo-oophorectomy (USO), and bilateral salpingooophorectomy (BSO) including total hysterectomy. All 32 patients underwent surgery, and the number of UOC, USO, and BSO procedures was 4 (12%), 20 (63%), and 8 (25%) respectively (Table 3) . UOC cases undertook re-staging operation later.
IHC analysis of four hereditary related genes was conducted on tumor blocks. None of the samples showed loss of expression, as indicated by negative IHC staining, but weak staining was found for MSH2 (n = 1, 3%) and BRCA2 (n = 6, 19%). The pathology of the patient with weak MSH2 staining was mucinous and that of the patients with weak BRCA2 staining was serous (n = 2) or mucinous (n = 3) (Table 4) .
Interestingly, one patient with a serous borderline tumor was also diagnosed with a serous cystadenocarcinoma at the same time. Before the operation, her serum CA-125 was elevated (554.7 U/mL) and the computed tomography (CT) image indicated a malignant appearance for the right ovarian mass. The patient underwent BSO, total hysterectomy, pelvic lymph node dissection, total omentectomy, and an appendectomy for surgical staging.
Based on surgical findings from frozen biopsy the left ovary looked normal but the right ovarian mass was malignant.
The final pathologic finding was serous borderline tumor in the left ovary and serous cystadenocarcinoma in the right ovary. We obtained IHC data corresponding to both tumors, which showed the same result of weak BRCA2 staining and strong staining for the other markers for both tumors.
Discussion
There were 2,124 newly detected cases of ovarian cancer and the estimated mortality was 987 in Korea. 16 tumors are high-grade serous carcinoma. These two types differ in their pathogenesis, molecular events, behavior, and prognosis, and it is rare for a low-grade serous carcinoma to change to a high-grade serous carcinoma. 17, 18 But hereditary background has not been fully studied so far.
Difficulties with ovarian carcinomas are hardness to diagnose early and cost to treat them.
Most ovarian carcinoma patients do not have specific symptoms and 16% are asymptomatic at the time of diagnosis. 19 As a result, when they are diagnosed the stage tends to be more advanced. In addition, treatment costs for cancer are increasing. 20 Early diagnosis of ovarian cancer is difficult, but very important. We do not know exactly what proportion of BOT represent suspicious ovarian carcinoma or a hereditary cancer risk, although it is believed to be small.
BOT are a transitional category between benign and malignant. The prognosis of BOTs is generally good, 21 but they can recur or change cancer type. In one study, 28
women (17%) showed recurrence as either BOT (23 womens) or carcinoma (5 womens) after fertility-sparing surgery for BOT. 22 In another study, the recurrence rate of serous BOT with non-invasive implants was 44% and the mortality was 25%. 5 In some cases BOT is diagnosed concurrently with serous cystadenocarcinoma, as seen in our study. . We should therefore consider hereditary risk, rather than somatic mutation.
There are studies for markers of ovarian tumor. Expression of p53 and Jab1 proteins is showed positive trend of ovarian cancer, but expression of p27 protein is related negative effect. 30 In other hands, benign tumor, such as endometriosis, is associated Estrogen receptor gene polymorphisms. 
